Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

BUY
$0.44 - $1.22 $132 - $366
300 Added 1.53%
19,891 $13,000
Q4 2023

Jan 16, 2024

SELL
$0.23 - $1.74 $39,111 - $295,888
-170,051 Reduced 89.67%
19,591 $9,000
Q3 2023

Oct 24, 2023

BUY
$1.41 - $2.31 $3,238 - $5,306
2,297 Added 1.23%
189,642 $280,000
Q2 2023

Jul 25, 2023

SELL
$1.5 - $3.04 $2,337 - $4,736
-1,558 Reduced 0.82%
187,345 $301,000
Q1 2023

Apr 14, 2023

BUY
$2.8 - $5.46 $20,132 - $39,257
7,190 Added 3.96%
188,903 $547,000
Q4 2022

Feb 08, 2023

SELL
$2.85 - $5.18 $7,481 - $13,597
-2,625 Reduced 1.42%
181,713 $596,000
Q3 2022

Oct 25, 2022

BUY
$2.85 - $8.73 $339,477 - $1.04 Million
119,115 Added 182.63%
184,338 $697,000
Q2 2022

Aug 12, 2022

BUY
$4.69 - $9.84 $305,895 - $641,794
65,223 New
65,223 $508,000
Q2 2020

Jul 28, 2020

SELL
$7.53 - $14.93 $179,003 - $354,915
-23,772 Closed
0 $0
Q1 2020

Apr 21, 2020

BUY
$5.69 - $17.78 $14,828 - $46,334
2,606 Added 12.31%
23,772 $202,000
Q4 2019

Feb 12, 2020

BUY
$10.89 - $16.79 $10,149 - $15,648
932 Added 4.61%
21,166 $349,000
Q3 2019

Nov 07, 2019

SELL
$12.03 - $19.94 $2,682 - $4,446
-223 Reduced 1.09%
20,234 $286,000
Q2 2019

Aug 06, 2019

SELL
$19.05 - $41.04 $103,917 - $223,873
-5,455 Reduced 21.05%
20,457 $411,000
Q1 2019

May 06, 2019

BUY
$28.4 - $41.74 $5,594 - $8,222
197 Added 0.77%
25,912 $1.03 Million
Q4 2018

Feb 11, 2019

SELL
$30.9 - $42.97 $9,733 - $13,535
-315 Reduced 1.21%
25,715 $893,000
Q3 2018

Nov 14, 2018

SELL
$35.05 - $43.5 $13,143 - $16,312
-375 Reduced 1.42%
26,030 $1.08 Million
Q2 2018

Aug 14, 2018

SELL
$35.15 - $51.45 $53,674 - $78,564
-1,527 Reduced 5.47%
26,405 $970,000
Q1 2018

May 14, 2018

BUY
$18.0 - $48.35 $46,926 - $126,048
2,607 Added 10.29%
27,932 $1.09 Million
Q4 2017

Feb 14, 2018

BUY
$13.2 - $18.1 $22,690 - $31,113
1,719 Added 7.28%
25,325 $458,000
Q3 2017

Nov 13, 2017

BUY
$13.25 - $17.05 $159 - $204
12 Added 0.05%
23,606 $391,000
Q2 2017

Aug 14, 2017

BUY
N/A
23,594
23,594 $330,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.